Skip to main content
. Author manuscript; available in PMC: 2022 Jun 2.
Published in final edited form as: Nat Chem Biol. 2021 Dec 2;18(4):360–367. doi: 10.1038/s41589-021-00900-9

Fig. 5 |. Ammocidin A inhibits leukemia growth in vivo.

Fig. 5 |

a, Experimental scheme for xenograft experiments—grey dots indicate assessment of human MV-4–11 chimerism in blood only, pink dots on days of ammocidin dosing, and black dot for terminal analysis on day 28 (e.g. assessment of chimerism in the blood, marrow, and spleen); b, Assessment of human MV-4–11 chimerism in the blood, bone marrow, and spleen at day 28; bars represent mean ± S.E.M for each group. Statistical differences between treatment groups were determined using a two-sided Wilcox test with Holm-Bonferroni correction for multiple comparisons (n = 5 – 7 mice per group, ** = P < 0.01, exact P values provided in source data); c, Immunohistochemistry against human CD45 in day 28 marrow showing dose dependent decrease in leukemia burden.